Amneal Pharmaceuticals, Class Stock Fundamentals
| AMRX Stock | USD 8.39 0.07 0.84% |
Amneal Pharmaceuticals, Class fundamentals help investors to digest information that contributes to Amneal Pharmaceuticals,'s financial success or failures. It also enables traders to predict the movement of Amneal Stock. The fundamental analysis module provides a way to measure Amneal Pharmaceuticals,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amneal Pharmaceuticals, stock.
At this time, Amneal Pharmaceuticals,'s EBIT is fairly stable compared to the past year. Research Development is likely to rise to about 200.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 154.9 M in 2024. Amneal | Select Account or Indicator |
Amneal Pharmaceuticals, Class Company Current Valuation Analysis
Amneal Pharmaceuticals,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Amneal Pharmaceuticals, Current Valuation | 5.17 B |
Most of Amneal Pharmaceuticals,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amneal Pharmaceuticals, Class is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Amneal Current Valuation Historical Pattern
Today, most investors in Amneal Pharmaceuticals, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amneal Pharmaceuticals,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Amneal Pharmaceuticals, current valuation as a starting point in their analysis.
Amneal Pharmaceuticals, Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Amneal Pharmaceuticals, Class has a Current Valuation of 5.17 B. This is 64.0% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 68.9% higher than that of the company.
Amneal Pharmaceuticals, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amneal Pharmaceuticals,'s current stock value. Our valuation model uses many indicators to compare Amneal Pharmaceuticals, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amneal Pharmaceuticals, competition to find correlations between indicators driving Amneal Pharmaceuticals,'s intrinsic value. More Info.Amneal Pharmaceuticals, Class is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . At this time, Amneal Pharmaceuticals,'s Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amneal Pharmaceuticals,'s earnings, one of the primary drivers of an investment's value.Amneal Pharmaceuticals,'s Earnings Breakdown by Geography
Amneal Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amneal Pharmaceuticals,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amneal Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing Amneal Pharmaceuticals, by comparing valuation metrics of similar companies.Amneal Pharmaceuticals, is currently under evaluation in current valuation category among its peers.
Amneal Pharmaceuticals, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amneal Pharmaceuticals,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amneal Pharmaceuticals,'s managers, analysts, and investors.Environmental | Governance | Social |
Amneal Fundamentals
| Return On Equity | -1.86 | ||||
| Return On Asset | 0.0594 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 5.17 B | ||||
| Shares Outstanding | 309.84 M | ||||
| Shares Owned By Insiders | 53.34 % | ||||
| Shares Owned By Institutions | 46.26 % | ||||
| Number Of Shares Shorted | 3.5 M | ||||
| Price To Earning | 230.50 X | ||||
| Price To Book | 86.10 X | ||||
| Price To Sales | 1.45 X | ||||
| Revenue | 2.39 B | ||||
| Gross Profit | 791.46 M | ||||
| EBITDA | 500.78 M | ||||
| Net Income | (48.72 M) | ||||
| Cash And Equivalents | 87.33 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 2.75 B | ||||
| Current Ratio | 1.74 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | 345.58 M | ||||
| Short Ratio | 4.23 X | ||||
| Earnings Per Share | (0.86) X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 10.5 | ||||
| Number Of Employees | 7.85 K | ||||
| Beta | 1.18 | ||||
| Market Capitalization | 3.88 B | ||||
| Total Asset | 3.47 B | ||||
| Retained Earnings | (490.18 M) | ||||
| Working Capital | 531.27 M | ||||
| Current Asset | 753.39 M | ||||
| Current Liabilities | 310.2 M | ||||
| Net Asset | 3.47 B |
About Amneal Pharmaceuticals, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amneal Pharmaceuticals, Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amneal Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amneal Pharmaceuticals, Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 458.2 M | 481.1 M | |
| Total Revenue | 2.4 B | 1.7 B | |
| Cost Of Revenue | 1.6 B | 1 B | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.12 | 0.10 | |
| Research And Ddevelopement To Revenue | 0.07 | 0.07 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 13.59 | 9.22 | |
| Ebit Per Revenue | 0.09 | 0.14 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.